Cardiovascular diseases (CVD) are the number one cause of morbidity and death
worldwide. As estimated by the WHO, the global death rate from CVD is 31% wherein, a …

elaboration. Aspirin can also directly scavenge hydroxyl radicals to form the 2, 3-and 2, 5-
dihydroxybenzoate derivatives, which themselves serve as markers of oxidative stress25 …

Background: The currently recommended duration of dual antiplatelet therapy (DAPT) in
drug-eluting stent (DES) recipients is 12 months to reduce the risk of late stent thrombosis …

The content of these European Society of Cardiology (ESC) Guidelines has been published
for personal and educational use only. No commercial use is authorized. No part of the ESC …

The burden of cardiovascular disease (CVD) among patients with diabetes is substantial.
Individuals with diabetes are at 2-to 4-fold increased risk of cardiovascular events compared …

Objectives: This study was designed to determine if aspirin resistance is associated with
clinical events. Background: Aspirin resistance, defined by platelet function testing and …

Objective To determine if there is a relation between aspirin “resistance” and clinical
outcomes in patients with cardiovascular disease. Design Systematic review and meta …

Aspirin resistance is the inability of aspirin to reduce platelet production of thromboxane A 2
and thereby platelet activation and aggregation. Increasing degrees of aspirin resistance …

Arachidonic acid is one of the most abundant and ubiquitous ω-6 polyunsaturated fatty acid,
present in esterified form in the membrane phospholipids of all mammalian cells and …

This article discusses platelet active drugs as part of the Seventh American College of Chest
Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based …